Mefenorex

Summary

Mefenorex (CHEMBL2110962) is an approved small molecule (ATC A08AA09); indicated across 1 condition including obesity disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A08AA09
• Indications: 1 condition
• Chemistry: 211.73 Da · C12H18ClN

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110962
Name	Mefenorex
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	21777
ATC	A08AA09
Molecular formula	C12H18ClN
Molecular weight	211.73
InChIKey	XXVROGAVTTXONC-UHFFFAOYSA-N

SMILES: CC(CC1=CC=CC=C1)NCCCCl

IUPAC name: N-(3-chloropropyl)-1-phenylpropan-2-amine

Also known as: Mefenorex, SID170465601, MEFENOREX

Parent form; salt/anhydrous children: CHEMBL2106838

Patent coverage: 586 distinct patent families (2,529 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obesity disorder	4	MONDO:0011122	EFO:0001073

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).